Open AccessEnzalutamide: an evidence-based review of its use in the treatment of prostate cancer
Author(s) -
Emmanuel S. Antonarakis,
Golshayan
Publication year - 2013
Publication title -
core evidence
Language(s) - English
Resource type - Journals
eISSN - 1555-175X
pISSN - 1555-1741
DOI - 10.2147/ce.s34747
Subject(s) - enzalutamide , medicine , prostate cancer , prostate , oncology , cancer , urology , androgen receptor
Enzalutamide is an oral androgen receptor (AR) signaling inhibitor that was specifically engineered to overcome castration-resistant prostate cancer (CRPC) harboring AR amplification or overexpression. Enzalutamide has demonstrated significant activity in men with metastatic CRPC.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom